Clinical trial · Observational
Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
NCT05025969CI-TRIAL-00078430NTRK FusioncompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective, mono centric, exploratory study to assess the incidence of a genomic alteration: NTRK gene fusion, in adult gliomas and brain metastases.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brain metastasis data collection | Other | — | UNRESOLVED |
| Glioma data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Glioma
- description
- (20 grade II gliomas, 20 grade III gliomas and 20 glioblastomas)
- interventionNames
- Other: Glioma data collection
- label
- Brain metastasis
- description
- The "brain metastasis" cohort consists of 80 patients, including 30 patients for whom the matched primary tumour is available
- interventionNames
- Other: Brain metastasis data collection
Primary outcomes (1)
- measure
- NTRK Fusion
- timeFrame
- through study completion, an average of 12 months
- description
- Incidence of NTRK gene fusion identified by RNAseq in glioma and brain metastasis tumour samples.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult male or female subject; * Glioma or brain metastasis operated on in our institution, histologically confirmed (WHO classification 2016); * Subject with a frozen tumour sample \< 5 years old; * Subject for whom all clinico-radiological data are available; * Subject affiliated to a health insurance scheme; * Subject who has been informed of the research and who has not indicated his opposition to the use of his medical data and who has signed a consent for the use of his tumour sample. Exclusion Criteria: * Patient under legal protection, guardianship or deprived of liberty by judicial or administrative decision * Biological samples not available and/or in insufficient quantity for analysis
References
Publications (0)
Data not yet available
No reference posted for this study.